Point-of-Care Diagnostic Tools for Surveillance of SARS-CoV-2 Infections

Dhanasekaran Sakthivel1†, David Delgado-Diaz1†, Laura McArthur2, William Hopper1, Jack S. Richards1,3,4 and Charles A. Narh1,3,4*

1 ZiP Diagnostics Pty Ltd., Collingwood, VIC, Australia, 2 School of Medicine, Monash University, Clayton, VIC, Australia, 3 Department of Life Sciences, Burnet Institute for Medical Research, Melbourne, VIC, Australia, 4 Department of Medicine, University of Melbourne, Melbourne, VIC, Australia

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a recently emerged and highly contagious virus that causes coronavirus disease 2019 (COVID-19). As of August 24, 2021, there were more than 212 million confirmed COVID-19 cases and nearly 4.4 million deaths reported globally. Early diagnosis and isolation of infected individuals remains one of the most effective public health interventions to control SARS-CoV-2 spread and for effective clinical management of COVID-19 cases. Currently, SARS-CoV-2 infection is diagnosed presumptively based on clinical symptoms and confirmed by detecting the viral RNA in respiratory samples using reverse transcription polymerase chain reaction (RT-PCR). Standard RT-PCR protocols are time consuming, expensive, and technically demanding, which makes them a poor choice for large scale and point-of-care screening in resource-poor settings. Recently developed isothermal nucleic acid amplification tests (iNAAT), antigen and/or serological tests are cost-effective to scale COVID-19 testing at the point-of-care (PoC) and for surveillance activities. This review discusses the development of rapid PoC molecular tools for the detection and surveillance of SARS-CoV-2 infections.

Keywords: COVID-19, SARS-CoV-2, point-of-care, diagnostics, isothermal amplification (LAMP), sample types, surveillance

INTRODUCTION

The diagnosis of active SARS-CoV-2 infection is critical in epidemiological surveillance, infection control and contact tracing, clinical management, and for monitoring the impact of interventions against the spread of the virus. Current diagnostic tests fall into three main categories: molecular tests that detect the SARS-CoV-2 RNA, antigen tests that detect the presence of specific viral antigens, and serological tests that detect anti-SARS-CoV-2 immunoglobulins (Ig). COVID-19 diagnosis criteria vary among countries (1) but in every case, detection of SARS-CoV-2 RNA by reverse transcriptase PCR (RT-PCR) is considered a confirmatory diagnosis (2). However, RT-PCR is expensive and laborious; requiring viral RNA isolation, purification and reverse transcription to complementary DNA (cDNA) before amplification using PCR. Hence, it requires skilled personnel and dedicated laboratory space, thus limiting its use in resource-limited settings. More recently, serology and antigen-based test, and isothermal nucleic acid amplification test (iNAAT) have become available for the diagnosis of COVID-19 (Table 1). These tests have acceptable sensitivity and do not require sophisticated equipment, offer rapid turnaround time within an hour and can be
performed at the point-of-care (PoC). To date, several RT-PCR diagnostic kits and, to a lesser extent antigen/antibody-based detection tests, isothermal amplification tests, clustered regularly interspaced short palindromic repeats (CRISPR-) and sequencing-based detection tests have been approved by the Food and Drug Administration (FDA) via Emergency Use Authorization (EUA) for the diagnosis of COVID-19. This review discusses the molecular, serological, and antigen diagnostic tools for detecting SARS-CoV-2 infections, their potential use for PoC diagnosis of COVID-19 (Table 1).

ANTIBODY- AND ANTIGEN-BASED COVID-19 TESTING

Our understanding of immune response against SARS-CoV-2 infections has rapidly unfolded as millions of individuals have been infected. Seroconversion in infected individuals has been observed between 1 and 2 weeks post-symptom onset (3–9). Studies on the immune responses of SARS-CoV-2-infected patients have shown increased presence of follicular helper T cells, activated CD4+ and CD8+ T cells with the detection of Immunoglobulin A (IgA), IgM, and IgG against the SARS-CoV-2 spike (S), nucleocapsid (N) and envelope (E) proteins (6, 10–13). Antibodies against SARS-CoV-2 have been shown to persist at least 12 months post-infection in most individuals (14–18). The majority of SARS-CoV-2 rapid diagnostic tests detect the presence of anti-SARS-CoV-2 antibodies (IgG, and/or IgM) in plasma or serum of infected individuals (FDA.gov).

Immunoaassays for COVID-19 diagnosis target the most immunogenic proteins—N and S (6, 10, 11, 19–21). In serum and plasma specimens, anti-SARS-CoV-2 antibodies could be detected as early as 2 weeks post-symptom onset (21). However, infected individuals show different antibody profiles over the course of the disease (12, 22). SARS-CoV-2-specific IgA and IgM antibodies have been detected 5 days post-symptom onset while IgG was detected 14 days post-symptom onset (12, 22), indicating early and evolving infections, respectively. The majority of the immunoassays in use are based on enzyme linked immunosorbent assay (ELISA), immunochromatography (lateral-flow) and antigen microarray (6, 10, 20–23). ELISA offers high-throughput but requires experienced technicians, a laboratory space, and several other instruments, and thus, it is not feasible for PoC diagnosis. In contrast, lateral-flow-based assays are easy to use, do not require instruments, and have been developed and deployed as PoC tools for serological and antigen-based diagnosis of COVID-19 (24, 25).

In spite of their advantages (Table 1), serological tests are limited in the diagnosis of SARS-CoV-2 infections due to their poor sensitivity to detect mild and asymptomatic infections (26). In addition, reports of individuals who remain PCR-positive after seroconversion suggest that they may still be shedding viral RNA during the convalescent stage. However, this may not necessarily indicate the presence of viable virus (3, 4, 27–30). Therefore, serological tests may be limited to identification of past but not active infections. Considering their relatively lower cost and ease of use in comparison with RT-PCR, they could be used to initially screen vulnerable populations to estimate seropositivity rates.

In contrast to antibody tests, antigen tests detect the presence of specific SARS-CoV-2 antigens in respiratory samples. Oropharyngeal, nasal and nasopharyngeal specimens are the most compatible specimen types for the majority of COVID-19 antigen and NAAT methods (2, 31). Antigen tests are relatively more affordable than RT-PCR, and considerably sensitive when used during the infectious period of the disease (32, 33). They are recommended for routine testing among at risk populations (34, 35). To date, over 20 SARS-CoV-2 antigen tests have received FDA emergency use authorization, reporting analytical sensitivities down to 30 TCID50/mL and specificities of up to 99% (36).

MOLECULAR DETECTION OF SARS-CoV-2 INFECTIONS

Several NAAT tools have been developed to detect SARS-CoV-2 infections by amplifying the viral RNA from a wide range of sample types including nasal swabs and saliva samples. While RT-PCR is currently the gold standard for the detection of SARS-CoV-2 RNA due to its high sensitivity, other methods including recombinase polymerase amplification (RPA) and loop mediated isothermal amplification (LAMP, see Figure 1) have also been used for COVID-19 diagnosis (37–39). RT-PCR is expensive, laborious and requires skilled personnel, making it unsuitable for PoC diagnosis (37–39). The accuracy and sensitivity of RT-PCR is affected by the purity of the sample and/or extracted RNA. The global shortage of RNA extraction kits has had adverse impacts on COVID-19 diagnosis and control worldwide. Though extraction-free RT-qPCR protocols have been considered as alternatives for the standard SARS-CoV-2 RT-PCR method, laboratory optimizations are often required to minimize false-negative rates (40).

Several reports suggest that RT-PCR positivity does not necessarily correlate with clinical infectivity since respiratory samples may contain non-viable virus, which could persist in the body for several weeks during the convalescent stage of the disease (41–44). Viable virus can be cultured from samples with low RT-PCR cycle threshold (Ct) values while samples with high Ct values are less likely to contain culturable virus (3, 45–47), suggesting that individuals with high Ct values (usually those at later stages of the disease) are less likely to spread the virus than those with low Ct values (usually those in the acute phase of the disease).

The performance of NAATs on the detection of SARS-CoV-2 RNA has been extensively reviewed elsewhere (48–52). Due to the lack of standardization in the NAAT testing algorithms including sample types and target genes, it is difficult to compare the analytical performance of the various test types (Table 1). A study by Vogels and colleagues found that test sensitivity was comparable among most of the primer-probe sets with the exception of primer sets targeting the RNA dependent RNA polymerase (RdRp-SARSr) gene segment, which resulted in
lower sensitivity (53). Significant difference in sensitivity has been observed with commercial RT-PCR kits. For instance, Igloi and colleagues evaluated 13 commercial kits and reported analytical sensitivities that ranged from 3.3 to 330 viral RNA copies in the RT-PCR assays evaluated (54).

Published gene targets for the detection of SARS-CoV-2 have comparable specificity. While RT-PCR based commercial kits used by the China National Institute for Viral Disease Control and Prevention (CCDC) predominantly target the Open Reading Frame 1ab (orf1ab) and N genes (55), other commercially available RT-PCR kits target the RNA-dependent RNA polymerase (RdRP) and/or E genes (37). In other assays, multiple targets on the same gene are included in order to increase the test sensitivity, e.g., two targets on the N gene (56). The sensitivity of PCR-based detection has been improved with double strand excision of the target using the CRISPR gene-editing technique (38, 39, 57). The rising number of mutations in the viral genome, particularly in the S and orf1ab genes have raised concerns about the sensitivity of NAAT tools to detect SARS-CoV-2 including emerged variants—alpha (B.1.1.7), beta (B1.3.51), gamma (P.1), delta (B.1.617.2) and epsilon (B.1.427/B.1.429), which have been associated with high transmissibility and disease severity in many geographical regions (58, 59). It is important that NAAT diagnostic tools are routinely quality-checked to ensure that they detect all variants in circulation and meet international regulatory test performance criteria (60).

**SAMPLE TYPES FOR THE DETECTION OF SARS-CoV-2 RNA**

The sensitivity and performance of NAATs for accurate detection of SARS-CoV-2 relies on the specimen type and quality,
| Sample types used | RT-LAMP | RT-PCR (Gold standard) | Antigen assay | References |
|-------------------|---------|------------------------|---------------|------------|
| Upper respiratory: saliva, nasopharyngeal/oropharyngeal swabs | Yes | Yes | Yes | (95–97) |
| Lower respiratory: sputum, tracheal/bronchoalveolar aspirates | Yes | Yes | Yes | (94, 98–100) |

| Sample preparation/input | RT-LAMP | RT-PCR (Gold standard) | Antigen assay | References |
|--------------------------|---------|------------------------|---------------|------------|
| Crude sample preparation with lysis as input for amplification | Yes (cell lysates in lysis buffer compatible with LAMP) | Yes, RNA is extracted and purified using in-house reagents or commercial kits | Yes, cell lysates in suitable lysis buffer compatible with antigen assay | (96, 101–105) |
| Purified RNA as input for amplification | Yes | Yes | Antigen detection assay detects the SARS-CoV-2 surface proteins in the lysate | (37, 106, 107) |

| Test technology | RT-LAMP | RT-PCR (Gold standard) | Antigen assay | References |
|-----------------|---------|------------------------|---------------|------------|
| cDNA synthesis and amplification in the same reaction. | Yes; with commercially available reverse transcriptase and Bst DNA polymerase (possess strand displacement activity). E.g., NEB RT-LAMP mix | Yes, with commercially available reverse transcriptase and Taq DNA polymerase. E.g., TaqMan™ SARS-CoV-2 RT-PCR assay kit | Antigen detection assay uses monoclonal and/or polyclonal antibody specific to SARS-CoV-2 antigen | (65, 87, 94, 97, 102, 108–110) |

| Number of primers used | RT-LAMP | RT-PCR (Gold standard) | Antigen assay | References |
|------------------------|---------|------------------------|---------------|------------|
| At least 4 primers. Optional inclusion of 2 loop primers to speed up amplification | At least 2 primers. Optional inclusion of probe for real-time amplicon detection | Antigen detection assay uses monoclonal and/or polyclonal antibody specific to SARS-CoV-2 antigen | Targets viral proteins including spike and nucleocapsid. | N/A |

| Detection modality | RT-LAMP | RT-PCR (Gold standard) | Antigen assay | References |
|-------------------|---------|------------------------|---------------|------------|
| Instrumentation | Isothermal instrument (e.g., water bath/heat block) | Conventional/real-time PCR | Visual display of test results. Optional RDT reader | (103, 111) |
| Amplicon detection | Use of DNA intercalating dyes; color change and/or fluorescence detection, turbidity (magnesium pyrophosphate formation) | Fluorescence from DNA intercalating dyes or probes. | N/A | (87, 101, 108, 112) |
| Real-time detection | Yes (colorimetry and fluorescence detection) | Yes, fluorescence detection | Colorimetry and fluorescence detection | (87, 94) |

| Analytical performance | RT-LAMP | RT-PCR (Gold standard) | Antigen assay | References |
|-----------------------|---------|------------------------|---------------|------------|
| Sample-to-result | ≤1 h | ≥2 h | ≤0.5 h | (111) |
| Sensitivity | >95% | >93% | – | (11) |
| Specificity | >98% | >95% | – | – |

| Clinical performance | RT-LAMP | RT-PCR (Gold standard) | Antigen assay | References |
|---------------------|---------|------------------------|---------------|------------|
| Sensitivity | >94% | >90% | 75.8–100% | – |
| Specificity | >97% | >95% | 90–100% | – |

| Technological access | RT-LAMP | RT-PCR (Gold standard) | Antigen assay | References |
|---------------------|---------|------------------------|---------------|------------|
| Skill requirement and point-of-care deployability | Minimal training with basic laboratory requirements at the point-of-care; e.g., Clinica | Technical expertise in PCR and require well-equipped laboratory; Accredited research laboratories and hospitals | RDTs are user-friendly and test can be performed at home | (52, 91, 111, 113–116) |

RT-LAMP, reverse transcription loop-mediated isothermal amplification; RT-PCR, reverse transcription polymerase chain reaction; RNA, ribonucleic acid; cDNA, complementary deoxyribonucleic acid; NEB, New England BioLabs; N/A, not applicable. Analytical and Clinical validation data taken from the European Commission COVID-19 in vitro diagnostic devices and test methods database (111).
and the method used for processing the sample (37, 61–65). According to the WHO guidelines, testing for SARS-CoV-2 viral RNA requires respiratory samples. Upper respiratory specimens (nasopharyngeal, nasal, and/or oropharyngeal swabs) are most suited for testing early-stage infections, especially in asymptomatic or mild cases, while lower respiratory specimens (sputum and/or endotracheal aspirate or bronchoalveolar lavage) are recommended if for patients in the post-symptomatic phase of the disease and those with severe disease (2). In addition to respiratory samples, detection of viral RNA in serum and fecal samples collected from infected patients has also been reported, in particular where respiratory specimen gave a negative test result (55, 63, 64). However, these samples provide no clear utility for accurate detection of active SARS-CoV-2 infection (66, 67).

Specimens collected from infected individuals at the pre-symptomatic phase through to the hyperinflammatory phase of COVID-19 have resulted in variable positive rates. Studies have shown that a few days prior to and during the symptomatic phase, sputum and nasopharyngeal swab samples gave higher PCR positivity compared to fecal samples. However, the opposite has been observed during the recovery phase (63, 68), demonstrating the potential utility of fecal samples for monitoring viral clearance during the recovery phase. Although a few studies have been able to recover viable virus from fecal samples and anal swabs of convalescent patients (69–71), it is important to note that the presence of viral RNA in feces may not be an indication of active infection but an indication of residual viral RNA being cleared from the body via shedding of infected epithelial cells.

Recent evidence has demonstrated the utility of sputum and saliva as specimens for detection of SARS-CoV-2 (72–76) (Figure 1). For instance, a comparison of sample positivity using quantitative RT-PCR showed that sputum samples had higher positive rates than throat and nasal swabs collected from the same patient (65). Other studies have also reported differences in test sensitivity comparing saliva and nasopharyngeal swabs (73, 76–81). Saliva has been recommended for COVID-19 diagnosis, in particular for surveillance activities. Saliva sampling is non-invasive and suitable for COVID-19 screening in vulnerable populations and in settings where swabs are in limited supply (79, 82, 83). Sputum offers comparable sensitivity to other respiratory samples for the detection of SARS-CoV-2 RNA (74, 84) but its use is limited in situations where patients are unable to expectorate enough sputum for testing (72, 74). Unless collected properly, sputum sampling poses a high risk of viral transmission. Therefore, nasal swabs are preferred over sputum for the detection of SARS-CoV-2 RNA by NAAT methods (Figure 1).

During the early stages of the pandemic, detection of SARS-CoV-2 infection was severely impacted due to the shortage of RNA extraction kits (85, 86). In certain circumstances, these shortages led to delays in diagnosis, which hampered public health control efforts. To increase accessibility to molecular diagnostic tools for COVID-19, several research laboratories developed and optimized NAAT protocols to simplify and obviate the need for RNA purification (87, 88). More cost-effective molecular tools will be needed for SARS-CoV-2 surveillance during and post-pandemic.

**POINT-OF-CARE NAATS TO CONTROL THE SPREAD OF SARS-CoV-2**

The global spread of SARS-CoV-2 and its associated morbidity and mortality requires cost-effective laboratory equipment and PoC diagnostic tools for screening at-risk populations. PoC tests are easy to use and could be readily deployed at healthcare centers, schools and airports, and among vulnerable populations in aged care centers. RT-PCR is generally performed in centralized Biosafety level 2 (BSL2) laboratories and require regulatory approval to undertake COVID-19 testing (37–39). The complexities and the long wait times (≥2h) for RT-PCR test results makes it a less attractive tool for PoC diagnosis of COVID-19.

Developing a NAAT assay combining RNA extraction, cDNA synthesis and amplification in a single reaction tube, and without the need for sophisticated instruments offers huge prospects for COVID-19 diagnosis at the point-of-care (89, 90) (Figure 1). iNAATs including RPA and LAMP do not require expensive PCR equipment, tolerate crude lysates as input for amplification and can be integrated into portable isothermal instruments for PoC COVID-19 testing (91) (Figure 1). LAMP and RPA applications for SARS-CoV-2 detection have been reviewed elsewhere (89). Although iNAATs pose a higher risk of cross-contamination when compared to PCR-based diagnostic tools (Table 1), certain strategies have been shown to mitigate this problem (92–94). For instance, a pre-optimized closed-tube isothermal amplification coupled with quality control checks to eliminate false-positive and carry-over contamination would be optimum for SARS-CoV-2 testing (Figure 1). As countries scale-up efforts from control to elimination of SARS-CoV-2, cost-effective molecular tools including iNAAT that require minimal sample processing and can be integrated into portable isothermal devices for use at the point-of-care or in the field will be crucial to elimination efforts.

**CONCLUSION**

Laboratory testing for COVID-19 has been integral to public health efforts to control the spread of SARS-CoV-2 globally. However, the high cost and centralization of RT-PCR testing, and the long testing times from sample collection to receipt of test results could hamper SARS-CoV-2 control efforts. RT-LAMP-based testing methods overcome most of the limitations of RT-PCR and can be developed for PoC diagnosis of COVID-19. Since they are compatible with most sample types for detecting active SARS-CoV-2 infections. Thus, they could complement other low-cost diagnostic tools including RDTs and lateral-flow tests for monitoring SARS-CoV-2 transmission locally and globally. With the emergence of SARS-CoV-2 variants,
routine quality control checks of NAAT diagnostic tools will be needed to ensure that they meet regulatory and test performance requirements.

AUTHOR CONTRIBUTIONS

CN and JR conceived and designed the review. CN, DS, and DD-D conducted the literature review and wrote majority of the manuscript. LM and JR contributed to literature review and writing. JR and WH critically revised the manuscript. All authors have read and approved the manuscript for publication.

REFERENCES

1. Benitez MA, Velasco C, Sequeira AR, Henriquez J, Menezes FM, Paolucci F. Responses to COVID-19 in five Latin American countries. Health Policy and Technology. (2020) 9:525–59. doi: 10.1016/j.hipt.2020.08.014
2. WHO. Diagnostic Testing for SARS-CoV-2: Interim Guidance. Available online at: https://apps.who.int/iris/bitstream/handle/10665/334254/WHO-2019-nCoV-laboratory-2020.6-eng.pdf?sequence=1&isAllowed=y (accessed April 20, 2021).
3. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-19. Nature. (2020) 581:465–9. doi: 10.1038/s41586-020-2196-x
4. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. (2020) 71:2027–34. doi: 10.1093/cid/ciaa344
5. Woelfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Mueller MA, et al. Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster. medRxiv [preprint]. (2020).
6. Okba NMA, Muller MA, Li W, Wang C, GeurtvsankenKessel CH, Corman VM, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerging Infect Dis. (2020) 26:1478–88. doi: 10.3202/eid2607.200841
7. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J Clin Microbiol. (2020) 58:e00461–20. doi: 10.1128/JCM.00461-20
8. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. (2020) 26:845–8. doi: 10.1038/s41591-020-0987-1
9. Wang WY, Lim SH, Seng EH. Cross-reaction of sera from COVID-19 patients with SARS-CoV-2 antibodies. Ann Acad Med Sing. (2020) 49:523–6. doi: 10.4172/annals-acadmedsg.2020120
10. Haveri A, Smura T, Kuivanen S, Osterlund P, Hepojoki J, Ikonen N, et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Eurosurveillance. (2020) 25. doi: 10.2807/1560-7917.ES.2020.25.11.200266
11. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. (2020) 579:270–3. doi: 10.1038/s41586-020-2951-z
12. Guo L, Ren L, Yang S, Xiao M, Chang Y, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. (2020) 71:778–85. doi: 10.1093/cid/ciaa310
13. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. (2020) 26:453–5. doi: 10.1038/s41591-020-0891-2
14. Haveri A, Ekstrom N, Solastie A, Virta C, Osterlund P, Isosaiu E, et al. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. Eur J Immunol. (2021) 1–12. doi: 10.1002/eji.202149335
15. Alfano G, Fontana F, Morisi N, Giaroni F, Mori G, Guaraldi G, et al. One-year persistence of neutralizing anti-SARS-CoV-2 antibodies in dialysis patients recovered from COVID-19. Hemod. (Int. 2021) 25:E53–6. doi: 10.1111/hdi.12963
16. She Q, Xiao K, Yang H, Liu B, Pang X, Du J, et al. Antibodies can last for more than one year after SARS-CoV-2 infection: a follow-up study from survivors of COVID-19. Front Med. (2021) 8:967. doi: 10.3389/fmed.2021.684864
17. Wang Z, Muecksf, Schafer-Babajev D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. (2021) 595:426–31. doi: 10.1038/s41586-021-03696-9
18. Sherina N, Piralla A, Du L, Wan H, Kumagi-Braesch M, Andrell J, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. Med. (2021) 2:281–95 e4. doi: 10.1016/j.med.2021.02.001
19. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. (2020) 181:281–92 e6. doi: 10.1016/j.cell.2020.11.032
20. Diao B, Wen K, Chen J, Liu Y, Yuan Z, Han C, et al. Diagnosis of acute respiratory syndrome coronavirus 2 infection by detection of nucleocapsid protein. medRxiv [preprint]. (2020). doi: 10.1101/2020.07.03.2003524
21. Amanat F, Stadlbauer D, Strohsmeier S, Nguyen TH, Chimokov V, Mcmahon M, et al. A serological assay to detect SARS-CoV-2 serocconversion in humans. Nat Med. (2020) 26:1033–6. doi: 10.1038/s41591-020-0913-5
22. Zhang P, Gao Q, Wang T, Ke Y, Mo F, Jia R, et al. Evaluation of recombinant nucleocapsid and spike proteins for serological diagnosis of novel coronavirus disease 2019 (COVID-19). medRxiv. (2020) 2020:36954. doi: 10.1101/2020.03.17.20036954
23. Khan S, Nakajima R, Jain A, de Assis RR, Jasinskas A, Obiero JM, et al. Analysis of serologic cross-reactivity between common human coronaviruses and SARS-CoV-2 using coronavirus antigen microarray. bioRxiv [preprint]. (2020). doi: 10.1101/2020.03.24.20042382
24. Wu YL, Teng WP, Lin CH, Lee TF, Chung MY, Huang CH, et al. Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2. J Infect. (2020) 81:435–42. doi: 10.1016/j.jinf.2020.06.023
25. Michel M, Bouam A, Edouard S, Fenollar F, Di Pinto F, Mege JL, et al. Evaluating ELISA, immunofluorescence, and lateral flow assay for SARS-CoV-2 serologic assays. Front Microbiol. (2020) 11:597529. doi: 10.3389/fmicb.2020.597529
26. Liu ZL, Liu Y, Wang LG, Xiang TX, Le AP, Liu P, et al. Antibody profiles in mild and severe cases of COVID-19. Clin Chem. (2020) 66:1162–4. doi: 10.1093/clinchem/hvaa137
27. Liu WD, Chang SY, Wang JT, Tsai MJ, Hung CC, Hsu CL, et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19. J Infect. (2020) 81:318–56. doi: 10.1111/jinf.2020.03.063
28. Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, et al. Diagnostic value and dynamic variability of antibody in coronavirus disease 2019. Int J Infect Dis. (2020) 94:49–52. doi: 10.1016/j.ijid.2020.03.065
29. Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, et al. Viral kinetics and antibody responses in patients with COVID-19. medRxiv [preprint]. (2020). doi: 10.1101/2020.03.24.20042382

FUNDING

This work was supported by the National Health and Medical Research Council (NHMRC) of Australia (APP1161076 to JR). Burnet Institute received funding from the NHMRC Independent Research Institutes Infrastructure Support Scheme, and the Victorian State Government Operational Infrastructure Support Scheme. CN was partly supported by a COVID-19 grant (Ref. No. BSAC-COVID-64) from the British Society for Antimicrobial and Chemotherapy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
30. Agarwal V, Venkatakrishnan A, Puranik A, Kirkup C, Lopez-Marquez A, Challenor DW, et al. Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity. Cell Death Dis. (2020) 6:1–9. doi: 10.1038/s41420-020-00373-y

31. CDC. Interim Guidance for Antigen Testing for SARS-CoV-2. (2020). Available online at: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html#previous (accessed April 23, 2021).

32. Nordgreen J, Sharma S, Olsson H, Jambarg M, Falkborn T, Svensson L, et al. SARS-CoV-2 rapid antigen test: high sensitivity to detect infectious virus. J Clin Virol. (2021) 140:104846. doi: 10.1016/j.jcv.2021.104846

33. Pickering S, Batra R, Merrick B, Snell MB, Nebbia G, Douthwaite S, et al. Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. Lancet Microbe. (2021) 2:e461–71. doi: 10.1016/S2666-5247(21)00143-9

34. Larimore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci Adv. (2021) 7:eabd5393. doi: 10.1126/scradv.abd5393

35. Mina MJ, Parker R, Larimore DB. Rethinking Covid-19 test sensitivity - a strategy for containment. N Engl J Med. (2020) 383:120. doi: 10.1056/NEJMmp2025631

36. FDA. In Vitro Diagnostics EUA. (2021). Available online at: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/itro-diagnostics-eua (accessed January 15, 2021).

37. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Schmitz I, et al. Molecular detection of SARS-CoV-2 and 6 other respiratory viruses on a single chip. Lancet Microbe. (2020) 1:695–704. doi: 10.1016/S2666-5247(20)30172-5

38. Metsky HC, Freije CA, Kosoko-Thoroddsen T-SF, Sabeti PC, Myhrvold NF, Okba N, et al. Duration and key determinants of infectious virus shedding of SARS-CoV-2 in infected patients. Cell Death Disc. (2021) 2:e13–22. doi: 10.1016/S2666-5247(20)30172-5

39. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of severe acute respiratory syndrome coronavirus 2. J Clin Lab Anal. (2021) 35:e23643. doi: 10.1002/jcla.23643

40. van Kasteren PB, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den Brandt A, et al. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. J Clin Virol. (2020) 128:104412. doi: 10.1016/j.jcv.2020.104412

41. Krismawati H, Mahendra C, Hartanto A, Rokhmad MF, Sandi S, Irwanoto A. Comparison study of commercial COVID-19 RT-PCR kits propose an approach to evaluate their performances. medRxiv [preprint]. (2021). doi: 10.1101/2021.01.20.21250143

42. CDC. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. (2020). Available online at: https://www.fda.gov/media/134922/download (accessed April 29, 2021).

43. van Kasteren PB, ten Berge AH, van de Vijver D, Hamers MM, Haagmans BL, Lamers MM, et al. Viral RNA load as determined by cell culture as a management tool for the discharge of SARS-CoV-2 patients from infectious disease wards. Lancet Infect Dis. (2020) 20:20025874. doi: 10.1016/j.lancid.2020.20025874

44. Domnich A, De Pace V, Pennati BM, Caliguri P, Varesano S, Bruzzone B, et al. Evaluation of extraction-free RT-qPCR methods for SARS-CoV-2 diagnostics. Arch Virol. (2021) 166:2825–8. doi: 10.1007/s00705-021-05165-0

45. La Scala B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. (2020) 39:10359. doi: 10.1007/s10018-020-03913-9

46. McCallum M, Bassi J, De Marco A, Chen A, Walls AC, Di Julio J, et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science. (2021) 373:648–54. doi: 10.1126/science.ab7994

47. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are emerging in India. Nat Med. (2021) 27:1131–3. doi: 10.1038/s41591-021-01397-4

48. FDA. Genetic Variants of SARS-CoV-2 May Lead to False Negative Results With Molecular Tests for Detection of SARS-CoV-2 Letter to Clinical Laboratory Staff and Health Care Providers. (2021). Available online at: https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2 (accessed August 05, 2021).

49. Kim YJ, Ko JH, Kim Y, Kim YJ, Kim JM, Chung YS, et al. Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. J Korean Med Sci. (2020) 35:e86. doi: 10.3346/jkms.2020.35.e86

50. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. (2020) 20:689–96. doi: 10.1016/S1473-3099(20)30198-5

51. Wu Y, Guo C, Tang L, Hong Z, Zhao J, Dong X, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. (2020) 5:434–5. doi: 10.1016/S2542-2641(20)30083-2

52. Xie C, Jiang L, Huang G, Pu H, Gong B, Lin H, et al. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. Int J Infect Dis. (2020) 93:264–7. doi: 10.1016/j.ijid.2020.02.050

53. Yu F, Yan L, Wang N, Yang S, Wang L, Yang T, et al. Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients. Clin Infect Dis. (2020) 71:793–8. doi: 10.1093/cid/ciaa1280

54. Masiotta A, Margiotti K, Viola A, Cima A, Sparacino D, Giorlando C. Evaluation of SARS-CoV-2 viral RNA in fecal samples. Viril J. (2020) 17:86. doi: 10.1186/s12985-020-01359-1

55. Szymczak WA, Goldstein DY, Orner EP, Fecher RA, Yokoda RT, Skalka KA, et al. Utility of stool PCR for the diagnosis of COVID-19: comparison of respiratory syndrome coronavirus 2. J Clin Lab Anal. (2021) 35:e23643. doi: 10.1002/jcla.23643
of two commercial platforms. *J Clin Microbiol.* (2020) 58:e01369–20. doi: 10.1128/JCM.01369–20
68. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat Med.* (2020) 26:502–5. doi: 10.1038/s41591-020-0817-4
69. Xiao F, Sun J, Xu Y, Li F, Huang X, Li H, et al. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. *Emerg Infect Dis.* (2020) 26:1920–2. doi: 10.3201/eid2608.200681
70. Yuan C, Zhu H, Yang Y, Cai X, Xiang F, Wu H, et al. Viral loads in throat and anal swabs in children infected with SARS-CoV-2. *Emerg Microbes Infect.* (2020) 9:1233–5. doi: 10.1002/ewmi.21219
71. Yao H, Lu X, Chen Q, Xu K, Chen Y, Cheng M, et al. Patient-derived SARS-CoV-2 mutations impact viral replication dynamics and infectivity in vitro and with clinical implications in vivo. *Cell Dis.* (2020) 6:76. doi: 10.1038/s41421-020-00226-1
72. Han H, Luo Q, Mo F, Long L, Zheng W. SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients. *Lancet Infect Dis.* (2020) 20:655–6. doi: 10.1016/S1473-3099(20)30174-2
73. Mohammadi A, Esmaeilzadeh E, Li Y, Bosch R, Li J. SARS-CoV-2 detection in different respiratory sites: a systematic review and meta-analysis. *Ebiomedicine.* (2020) 59:102903. doi: 10.1016/j.ebiom.2020.102903
74. Wang K, Zhang X, Sun J, Ye J, Wang F, Hu J, et al. Differences of severe acute respiratory syndrome coronavirus 2 shedding duration in sputum and nasopharyngeal swab specimens among adult inpatients with coronavirus disease 2019. *Clin. Infect. Dis.* (2020) 158:1876–84. doi: 10.1016/j.clinfect.2020.06.015
75. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA.* (2020) 323:1843–4. doi: 10.1001/jama.2020.3786
76. Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi A, Nagy A, et al. Saliva as an alternative workflow for molecular diagnostic testing of SARS-CoV-2. *Cell Dis.* (2020) 158:1876–84. doi: 10.1016/j.celdis.2020.102903
77. Jamal AJ, Mohammad M, Coomes E, Powis J, Li A, Paterson A, et al. Saliva alternative to upper respiratory swabs for SARS-CoV-2 detection by direct rRT-PCR without the use of a commercial RNA extraction kit. *J Virol.* (2020) 285:113960. doi: 10.1128/JVI.00776-20
78. Williams E, Bond K, Zhang B, Putland M, Williamson DA. Saliva as a candidate for COVID-19 diagnostic testing: a meta-analysis. *Front Med.* (2020) 7:465. doi: 10.3893/fmed.2020.00465
79. Wylie AL, Fournier J, Casanova-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. *N Engl J Med.* (2020) 383:1283–6. doi: 10.1056/NEJMrc2009238
80. Becker D, Sandoval E, Amin A, De Hoff P, Leonetti N, Lim YW, et al. Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in the community setting. medRxiv [preprint]. doi: 10.1128/JCM.00776-20
81. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, et al. Exploring alternative swabs for use in SARS-CoV-2 detection in the community setting. medRxiv [preprint]. doi: 10.1016/j.jviromet.2020.113960
82. Patriquin G, Davis I, Heinstein C, MacDonald J, Hatchette TF, LeBlanc TM, et al. Rapid and extraction-free detection of SARS-CoV-2 from saliva by colorimetric reverse-transcription loop-mediated isothermal amplification. *Clin Chem.* (2020). doi: 10.1093/clinchem/hvaa267
83. Aminian A, Safari S, Razeghian-Jahromi A, Ghorbani M, Delaney CP. COVID-19 outbreak and surgical practice: unexpected contamination-free loop-mediated isothermal amplification based on the CRISPR/Cas9 cleavage. *ACS Sensors.* (2020) 5:1082–91. doi: 10.1021/acssensors.0c00034
84. Kellner MJ, Ross JJ, Schnabl J, Dekens MPS, Heinen R, Grishkovskaya I, et al. A rapid, highly sensitive and open-access SARS-CoV-2 detection assay for laboratory and home testing. *bioRxiv.* (2020) 2020.163997. doi: 10.1101/2020.06.23.166397
85. Lalli MA, Langmade JS, Chen X, Fronick CC, Sawyer CS, Burcea LC, et al. Rapid and extraction-free detection of SARS-CoV-2 from saliva by colorimetric reverse-transcription loop-mediated isothermal amplification. *Clin Chem.* (2021). doi: 10.1186/s12879-020-05484-8
86. Collier DA, Assennato SM, Warne B, Sethole N, Sharrocks K, Ritchie A, et al. New closed tube loop mediated isothermal amplification assay for prevention of product cross-contamination. *MethodsX.* (2014) 1:137–43. doi: 10.1016/j.mex.2014.08.009
87. Lalli MA, Langmade JS, Chen X, Fronick CC, Sawyer CS, Burcea LC, et al. Rapid and extraction-free detection of SARS-CoV-2 from saliva by colorimetric reverse-transcription loop-mediated isothermal amplification. *Clin Chem.* (2020). doi: 10.1093/clinchem/hvaa267
88. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Saliva as an invasive specimen for detection of SARS-CoV-2. *J Clin Microbiol.* (2020) 58:e00776-20. doi: 10.1128/JCM.00776-20
89. Byrne RL, Kay GA, Kontogianni K, Alajyoussi G, Brown L, Collins AM, et al. Saliva alternative to upper respiratory swabs for SARS-CoV-2 diagnosis. *Emerg Infect Dis.* (2020) 26:2770–1. doi: 10.3201/eid2611.200328
90. Jamal AJ, Mohammad M, Coomes E, Powis J, Li A, Paterson A, et al. Sensitivity of Nasopharyngeal Swabs and Saliva for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2. *Clin Infect Dis.* (2021) 71:1064–6. doi: 10.1093/cid/ciaa848
91. Patrignin G, Davis I, Heinstein C, McDonald J, Hatchette TF, LeBlanc JJ. Exploring alternative swabs for use in SARS-CoV-2 detection from the oropharynx and anterior nares. *J Virol.* (2020) 285:113948. doi: 10.1128/JVI.0113948
92. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, et al. Self-collected anterior nasal and saliva specimens versus health care worker-collected nasopharyngeal swabs for the molecular detection of SARS-CoV-2. *J Clin Microbiol.* (2020) 58:e01824-20. doi: 10.1128/JCM.01824-20
93. Levican-Asenjo JE, Almonacid LL, Valenzuela G, Garcia T, Rojas L, Serrano E, et al. Viral shedding dynamics reveals sputum as a reliable and cost-saving specimen for SARS-CoV-2 diagnosis within the first 10 days since symptom onset: a prospective cohort study. medRxiv [preprint]. doi: 10.1101/2020.08.30.20183389
94. Fomsgaard AS, Rosenstierne MW. An alternative workflow for molecular detection of SARS-CoV-2 - escape from the NA extraction kit-shortage, copenagen, denmark, March 2020. *Eurosurveillance.* (2020) 25:2000398. doi: 10.2807/1560-7917.ES.2020.25.14.2000398
95. Wei S, Kehl E, Djandji A, Morgan S, Whittier S, Mansukhani M, et al. Direct diagnostic testing of SARS-CoV-2 without the need for prior RNA extraction. *Sci Rep.* (2021) 11:1–6. doi: 10.1038/s41598-021-81487-y
104. Grant PR, Turner MA, Shin GY, Nastouli E, Levett LJ. Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic. *bioRxiv [preprint].* (2020). doi: 10.1101/2020.04.06.028316

105. Smyrlaki I, Ekman M, Lentini A, de Sousa NR, Papanicolaou N, Vondracek M, et al. Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR. *Nat Commun.* (2020) 11:1–12. doi: 10.1038/s41467-020-18611-5

106. Lim B, Ratcliffe J, Nawrot DA, Yu Y, Sanghani HR, Hsu CC, et al. Clinical validation of optimised RT-LAMP for the diagnosis of SARS-CoV-2 infection. *Sci Rep.* (2021) 11:16193. doi: 10.1038/s41598-021-95607-1

107. Graham TGW, Dugast-Darzacq C, Dailey GM, Nguyenla KH, Van Dis E, Esbin MN, et al. Open-source RNA extraction and RT-qPCR methods for SARS-CoV-2 detection. *PLoS ONE.* (2021) 16:e0246647. doi: 10.1371/journal.pone.0246647

108. Thi VLD, Herbst K, Boerner K, Meurer M, Kremer JP, Kirrmaier D, et al. A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. *Sci Transl Med.* (2020) 12:eabc7075. doi: 10.1126/scitranslmed.abc7075

109. Kriegova E, Fillerova R, Kvapil P. Direct-RT-qPCR detection of SARS-CoV-2 without RNA extraction as part of a COVID-19 testing strategy: from sample to result in one hour. *Diagnostics.* (2020) 10:6605. doi: 10.3390/diagnostics10080605

110. Ganguli A, Mostafa A, Berger J, Lim J, Araud E, Barik J, et al. Reverse transcription loop-mediated isothermal amplification assay for ultrasensitive detection of SARS-CoV-2 in saliva and viral transport medium clinical samples. *Anal Chem.* (2021) 93:7797–807. doi: 10.1021/acs.analchem.0c05170

111. EC. European Commission COVID-19 in vitro Diagnostic Devices and Test Methods Database. (2021). Available online at: https://covid-19-diagnostics.jrc.ec.europa.eu/ (accessed October 06, 2021).

112. Lee JYH, Best N, McAuley J, Porter JL, Seemann T, Schultz MB, et al. Validation of a single-step, single-tube reverse transcription loop-mediated isothermal amplification assay for rapid detection of SARS-CoV-2 RNA. *J Med Microbiol.* (2020) 69:1169–78. doi: 10.1099/jmm.0.001238

113. Ganguli A, Mostafa A, Berger J, Aydin MY, Sun F, de Ramirez SAS, et al. Rapid isothermal amplification and portable detection system for SARS-CoV-2. *Proc Natl Acad Sci USA.* (2020) 117:22727–35. doi: 10.1073/pnas.2014739117

114. Chen X, Zhou Q, Li S, Yan H, Chang B, Wang Y, et al. Rapid and visual detection of SARS-CoV-2 using multiplex reverse transcription loop-mediated isothermal amplification linked with gold nanoparticle-based lateral flow biosensor. *Front Cell Infect Microbiol.* (2021) 6:581239. doi: 10.3389/fcimb.2021.581239

115. Karthik K, Aravindh Babu RP, Dhama K, Chitra MA, Kalaiselvi G, Alagesan Senthilkumar TM, et al. Biosafety concerns during the collection, transportation, and processing of COVID-19 samples for diagnosis. *Arch Med Res.* (2020) 51:623–30. doi: 10.1016/j.arcmed.2020.08.007

116. Carter LJ, Garner LV, Smoot JW, Li Y, Zhou Q, Saveson CJ, et al. Assay techniques and test development for COVID-19 diagnosis. *ACS Central Sci.* (2020) 6:591–605. doi: 10.1021/acscentsci.0c00501

Conflict of Interest: ZiP Diagnostics is commercializing a COVID-19 point of care test. CN, DS, DD-D, WH, and JR have employment at ZiP. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.